Want to see FEMY full AI Analyst Report?
FEMY Stock Chart & Stats
$0.73
-$0.01(-0.91%)
At close: 4:00 PM EST
$0.73
-$0.01(-0.91%)
Day’s Range― - ―
52-Week Range$2.90 - $22.22
Previous CloseN/A
Volume25.00K
Average Volume (3M)50.79K
Market Cap
$9.09M
Enterprise Value$32.16
Total Cash (Recent Filing)$5.39M
Total Debt (Recent Filing)$4.73M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 12, 2026EPS Estimate
-1.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.43
Shares Outstanding3,019,534
10 Day Avg. Volume27,405
30 Day Avg. Volume50,788
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)3.88
Price to Sales (P/S)9.93
P/FCF Ratio-1.19
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$30.00Price Target Upside4009.59% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-4.53
Revenue Forecast (FY)$3.77M
Bulls Say, Bears Say
Bulls Say
Revenue Growth & Strong Gross MarginsSustained top-line growth alongside healthy gross margins indicates the products are gaining clinical adoption and carry durable unit economics. Over the next 2–6 months, this combination supports scalable revenue expansion as fixed-cost absorption improves and commercialization investments target higher-mix consumable sales.
Focused Women's Health Product PortfolioA diversified product set across fertility and non-surgical permanent birth control, plus reported regulatory approvals and in‑house scalable U.S. manufacturing, reduces execution friction. These structural assets support multi-market commercialization and lower supply constraints, aiding durable market penetration over several quarters.
Nasdaq Compliance & Governance Steps Reduce Listing RiskRestoring listing compliance and completing governance actions (director elections, auditor ratification) materially lowers delisting risk and strengthens oversight. That durable structural improvement preserves access to public capital and institutional investors, aiding financing and strategic execution over the medium term.
Bears Say
Large And Worsening Cash BurnSustained negative operating cash flow at this magnitude creates an ongoing need for external financing, which can dilute shareholders and constrain strategic investments. Absent a clear path to positive cash generation, runway and funding flexibility remain structural risks for the company's multi-quarter execution.
Severe Operating & Net Losses Vs RevenueExtremely negative operating and net margins signal a cost structure that does not scale with current revenues. These persistent losses imply weak operating leverage and poor returns; without meaningful margin improvement or substantial revenue acceleration, profitability remains an unresolved structural challenge.
Small Absolute Revenue Base Despite GrowthAlthough revenue is growing, the absolute scale is low, limiting fixed-cost absorption and leaving results sensitive to adoption swings. The small base means several quarters of sustained growth are required to change the financial profile materially, increasing execution risk and reliance on external capital in the interim.
Femasys News
FEMY FAQ
What was Femasys, Inc.’s price range in the past 12 months?
Femasys, Inc. lowest stock price was $2.90 and its highest was $22.22 in the past 12 months.
What is Femasys, Inc.’s market cap?
Femasys, Inc.’s market cap is $9.09M.
When is Femasys, Inc.’s upcoming earnings report date?
Femasys, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 22 days.
How were Femasys, Inc.’s earnings last quarter?
Currently, no data Available
Is Femasys, Inc. overvalued?
According to Wall Street analysts Femasys, Inc.’s price is currently Undervalued.
Does Femasys, Inc. pay dividends?
Femasys, Inc. does not currently pay dividends.
What is Femasys, Inc.’s EPS estimate?
Femasys, Inc.’s EPS estimate is -1.27.
How many shares outstanding does Femasys, Inc. have?
Femasys, Inc. has 3,019,534 shares outstanding.
What happened to Femasys, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Femasys, Inc.?
Currently, no hedge funds are holding shares in FEMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Femasys, Inc.
Femasys Inc., a biomedical company established in 2004 and based in Suwanee, Georgia, primarily targets the women's healthcare market within the United States. The firm's innovative product line includes permanent contraceptive solutions such as FemBloc and FemChec, alongside FemaSeed, which is an artificial insemination offering. For diagnostic purposes, Femasys provides FemCerv, a biopsy device utilized for endocervical curettage, and FemEMB, a product candidate intended for endometrial sampling to assist in the detection of uterine cancer. Additionally, the company markets its FemVue saline-air device across various international regions, including the U.S., Europe, Canada, and Japan. Its infertility-related products are supplied to obstetrician-gynecologists, other allied healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. The company also offers a range of non-surgical product technologies.
FEMY Stock 12 Month Forecast
Average Price Target
$30.00
▲(4009.59% Upside)
Technical Analysis
Retractable Technologies
―
Milestone Scientific
―
Precision Optics Corporation
―
NexGel Inc
―
―
Ownership Overview
16.27% Insiders
52.41% Mutual Funds
― Other Institutional Investors
29.26% Public Companies and
Individual Investors